| __timestamp | Biogen Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 1171036000 | 4932500000 |
| Thursday, January 1, 2015 | 1240400000 | 5037200000 |
| Friday, January 1, 2016 | 1478700000 | 5654900000 |
| Sunday, January 1, 2017 | 1630000000 | 6070200000 |
| Monday, January 1, 2018 | 1816300000 | 4681700000 |
| Tuesday, January 1, 2019 | 1955400000 | 4721200000 |
| Wednesday, January 1, 2020 | 1805200000 | 5483300000 |
| Friday, January 1, 2021 | 2109700000 | 7312800000 |
| Saturday, January 1, 2022 | 2278300000 | 6629800000 |
| Sunday, January 1, 2023 | 2533400000 | 7082200000 |
| Monday, January 1, 2024 | 0 | 8418299999 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, understanding cost structures is crucial. Eli Lilly and Company and Biogen Inc., two titans in the field, have shown distinct trends in their cost of revenue over the past decade. From 2014 to 2023, Eli Lilly's cost of revenue surged by approximately 43%, peaking in 2021. In contrast, Biogen's costs increased by about 116% during the same period, with a notable rise in 2023.
Eli Lilly's cost of revenue reflects its strategic investments in research and development, which have driven its growth. The company's peak in 2021, with costs reaching over 7 billion, underscores its commitment to innovation.
Biogen, while smaller in scale, has shown a consistent upward trend, with costs doubling since 2014. This growth highlights Biogen's expanding market presence and its focus on niche therapeutic areas.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Johnson & Johnson
Comparing Cost of Revenue Efficiency: Eli Lilly and Company vs Viatris Inc.
Cost of Revenue Comparison: Eli Lilly and Company vs Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Eli Lilly and Company and Telix Pharmaceuticals Limited's Expenses
Cost Insights: Breaking Down Eli Lilly and Company and Geron Corporation's Expenses
Analyzing Cost of Revenue: Biogen Inc. and Telix Pharmaceuticals Limited
Cost Insights: Breaking Down Biogen Inc. and CRISPR Therapeutics AG's Expenses
Comparing Cost of Revenue Efficiency: Biogen Inc. vs Amneal Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Biogen Inc. vs PTC Therapeutics, Inc.
Cost of Revenue: Key Insights for Biogen Inc. and Veracyte, Inc.
Cost of Revenue Trends: Biogen Inc. vs Taro Pharmaceutical Industries Ltd.